Both drugs are ultra-long-acting, meaning they are engineered to remain active in the body for longer than existing treatments like Novo's Wegovy and can be taken once a month
Any content on this Site, such as text, graphics, images, information obtained from, or contained on this Site are for informational purposes only
Dawed AY, Mari A, Brown A et al (2023) Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials
Dipeptidyl peptidase-4 inhibition with saxagliptin ameliorates angiotensin II-induced cardiac diastolic dysfunction in male mice
Drugs Its important to stress: GLP-1 drugs can be life-changing for people in severe metabolic crisis, but they are not a magic bullet